AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
James Cai, AstraZeneca's VP, Healthcare Policy Research, sat down with PharmAsia News' Shanghai bureau during the China Trials 2008 conference in November to discuss the burgeoning CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure there.
You may also be interested in...
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
Although China has made some progress, it still takes at least eight to nine months to get clinical trial approval there.